14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens

Cancer Letters

Volumn 254, Issue 1, 2007, Pages 137-145

  Quayle, Steven N ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

14 3 3 Sigma; Androgen receptor; LNCaP; Prostate cancer; Transcriptional activator

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; LUCIFERASE; METRIBOLONE; OLIGONUCLEOTIDE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

14-3-3 PROTEINS; ANDROGENS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUCIFERASES; MALE; METRIBOLONE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34447316146     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.003     Document Type: Article

References (40)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. Ryan C.J., and Eisenberger M. Chemotherapy for Hormone-Refractory Prostate Cancer: Now It's a Question of "When?". J. Clin. Oncol. 23 (2005) 8242-8246
3. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23 (2005) 8253-8261
4. Gregory C.W., Hamil K.G., Kim D., Hall S.H., Pretlow T.G., Mohler J.L., and French F.S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 58 (1998) 5718-5724
5. Culig Z., Steiner H., Bartsch G., and Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 12 (2005) 229-244
6. Heinlein C.A., and Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23 (2002) 175-200
7. Ueda T., Bruchovsky N., and Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277 (2002) 7076-7085
8. Ueda T., Mawji N.R., Bruchovsky N., and Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277 (2002) 38087-38094
9. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., and Wilson E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61 (2001) 4315-4319
10. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 (1999) 279-284
11. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R., and Gao A.C. Stat3 activation in prostatic carcinomas. Prostate 51 (2002) 241-246
12. Mora L.B., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
13. Debes J.D., Comuzzi B., Schmidt L.J., Dehm S.M., Culig Z., and Tindall D.J. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res. 65 (2005) 5965-5973
14. Hermeking H. The 14-3-3 cancer connection. Nat. Rev. Cancer 3 (2003) 931-943
15. Wang W., and Shakes D.C. Molecular evolution of the 14-3-3 protein family. J. Mol. Evol. 43 (1996) 384-398
16. Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., and Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401 (1999) 616-620
17. van Hemert M.J., Niemantsverdriet M., Schmidt T., Backendorf C., and Spaink H.P. Isoform-specific differences in rapid nucleocytoplasmic shuttling cause distinct subcellular distributions of 14-3-3 sigma and 14-3-3 zeta. J. Cell Sci. 117 (2004) 1411-1420
18. Wilker E.W., Grant R.A., Artim S.C., and Yaffe M.B. A structural basis for 14-3-3sigma functional specificity. J. Biol. Chem. 280 (2005) 18891-18898
19. Haendler B., Schuttke I., and Schleuning W.D. Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta. Mol. Cell Endocrinol. 173 (2001) 63-73
20. Snoek R., Rennie P.S., Kasper S., Matusik R.J., and Bruchovsky N. Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J. Steroid Biochem. Mol. Biol. 59 (1996) 243-250
21. Subramanian R.R., Zhang H., Wang H., Ichijo H., Miyashita T., and Fu H. Interaction of apoptosis signal-regulating kinase 1 with isoforms of 14-3-3 proteins. Exp. Cell Res. 294 (2004) 581-591
22. Rowan B.G., Weigel N.L., and O'Malley B.W. Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 275 (2000) 4475-4483
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
24. Wright M.E., Tsai M.J., and Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17 (2003) 1726-1737
25. Cleutjens K.B., van der Korput H.A., van Eekelen C.C., van Rooij H.C., Faber P.W., and Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11 (1997) 148-161
26. Kino T., Souvatzoglou E., De Martino M.U., Tsopanomihalu M., Wan Y., and Chrousos G.P. Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J. Biol. Chem. 278 (2003) 25651-25656
27. Kim Y.S., Jang S.W., Sung H.J., Lee H.J., Kim I.S., Na D.S., and Ko J. Role of 14-3-3 eta as a positive regulator of the glucocorticoid receptor transcriptional activation. Endocrinology 146 (2005) 3133-3140
28. Wakui H., Wright A.P., Gustafsson J., and Zilliacus J. Interaction of the ligand-activated glucocorticoid receptor with the 14-3-3 eta protein. J. Biol. Chem. 272 (1997) 8153-8156
29. Zilliacus J., Holter E., Wakui H., Tazawa H., Treuter E., and Gustafsson J.A. Regulation of glucocorticoid receptor activity by 14--3-3-dependent intracellular relocalization of the corepressor RIP140. Mol. Endocrinol. 15 (2001) 501-511
30. Geller J., Albert J., Nachtsheim D., Loza D., and Lippman S. Steroid levels in cancer of the prostate-markers of tumor differentiation and adequacy of anti-androgen therapy. Prog. Clin. Biol. Res. 33 (1979) 103-111
31. Benzinger A., Muster N., Koch H.B., Yates III J.R., and Hermeking H. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol. Cell Proteomics 4 (2005) 785-795
32. Benzinger A., Popowicz G.M., Joy J.K., Majumdar S., Holak T.A., and Hermeking H. The crystal structure of the non-liganded 14-3-3 sigma protein: insights into determinants of isoform specific ligand binding and dimerization. Cell Res. 15 (2005) 219-227
33. Sekimoto T., Fukumoto M., and Yoneda Y. 14-3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1). EMBO J. 23 (2004) 1934-1942
34. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., and Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277 (1997) 1501-1505
35. Cheng L., et al. Loss of 14-3-3sigma in prostate cancer and its precursors. Clin. Cancer Res. 10 (2004) 3064-3068
36. Lodygin D., Diebold J., and Hermeking H. Prostate cancer is characterized by epigenetic silencing of 14-3-3 sigma expression. Oncogene 23 (2004) 9034-9041
37. Mhawech P., Greloz V., Assaly M., and Herrmann F. Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol. Int. 55 (2005) 77-82
38. Urano T., et al. 14-3-3sigma is down-regulated in human prostate cancer. Biochem. Biophys. Res. Commun. 319 (2004) 795-800
39. Huang D., Liu X., Plymate S.R., Idowu M., Grimes M., Best A.M., McKinney J.L., and Ware J.L. Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12. Oncogene 23 (2004) 6881-6889
40. Han B., Xie H., Chen Q., and Zhang J.T. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol. Cancer Ther. 5 (2006) 903-912